Curated metabolic health research from PubMed and leading YouTube channels
Subscribe via RSSShowing 1-12 of 24 articles
Carotid ultrasound and CAC screening can identify heart disease risk factors early, potentially preventing heart attacks for less than $350.
Nick Norwitz discusses the groundbreaking VERVE-102 gene editing therapy for LDL cholesterol reduction, highlighting its potential impact on metabolic health.
A novel non-pharmacological approach significantly lowers major cardiovascular events in patients with ischemic heart disease, emphasizing the importance of autonomic function.
A recent study found a 62% reduction in LDL cholesterol at the highest dose, though cardiovascular outcomes were not improved. This raises important questions about long-term safety and metabolic health.
A decade after structured exercise, older adults with prediabetes show lasting health benefits, including reduced abdominal fat and improved fitness.
A groundbreaking study reveals gene editing can reduce LDL cholesterol by 62%, sparking debate on its implications for heart disease and metabolic health.
A recent Phase 1 trial tested VERVE-102, a gene-editing therapy for patients with familial hypercholesterolemia, highlighting its potential in lipid management.
VERVE-102 employs cutting-edge gene editing to target the PCSK9 gene, potentially transforming lipid metabolism and cardiovascular health. This innovative approach highlights the importance of effective delivery in gene therapy.
Extra-coronary calcification (ECC) may serve as a crucial cardiovascular risk marker for women, particularly those overlooked by traditional assessments.
This study reveals that epicardial fat volume is significantly higher in spondyloarthritis patients, linking it to increased cardiovascular risk and inflammation.
This study reveals that coronary artery calcification is linked to increased cardiovascular events in patients with advanced lung cancer, highlighting the need for careful monitoring.
This study highlights the relationship between elevated lipoprotein(a) and coronary artery calcium scoring in assessing cardiovascular risk, emphasizing the importance of monitoring these biomarkers.